Trial Profile
Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegloxenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Jiangsu Hansoh Pharmaceutical
- 08 Aug 2019 Status changed to completed as per results published in the British Journal of Clinical Pharmacology
- 08 Aug 2019 Results published in the British Journal of Clinical Pharmacology
- 25 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 May 2016, as reported by ClinicalTrials.gov.